Please Wait.....
Report
U.S. Hematology Oncology Market
Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research
The U.S. hematology oncology market is expected to reach USD 8.85 billion by 2035 from USD 3.39 billion in 2024, growing with a CAGR of 9.2% in the forecast period of 2025 to 2035.
Market Segmentation:
U.S. Hematology Oncology Market, By Disease Type (Lymphoma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Sickle Cell Disease (SCD), and Others), Treatment Type (Targeted Therapies & Small Molecules, Immunotherapies, Chemotherapy Drugs, Stem Cell Transplantation, Gene Therapy, and Others), Race (White or Unknown Race and Ethnically Diverse), End User (Hospitals, Specialized Clinics, Transplant Centers, Pharmaceutical & Biotech Companies, and Others) - Industry Trends & Forecast to 2035
Overview of U.S. Hematology Oncology Market Dynamics:
Driver
- Advancements In Diagnostic Technologies Transforming Hematology Oncology Detection And Treatment Approaches
Restraint
- Patient Non-Compliance With Treatment Regimens in Hematology Oncology Care
Opportunity
- Increase In The Number Of Collaborative Partnerships
Market Players:
The key market players operating in the U.S. hematology oncology market are listed below:
- Gilead Sciences, Inc.
- AbbVie Inc
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Sanofi (France)
- Dana-Farber Cancer Institute, Inc.
- The Johns Hopkins University
- The Johns Hopkins Hospital
- Johns Hopkins Health System
- UCLA Health
- Stanford Medicine
- The University of Texas MD Anderson Cancer Center
- Memorial Sloan Kettering Cancer Center
- CITY OF HOPE
- The Children's Hospital of Philadelphia
- Fred Hutchinson Cancer Center
- Vertex Pharmaceuticals Incorporated
- CRISPR Therapeutics
- Regeneron Pharmaceuticals Inc.
- bluebird bio, Inc.
- Editas Medicine
- Novartis AG
- Merck & Co., Inc.
- Cleveland Clinic
- Lilly
- Astellas Pharma Inc.
- Bayer AG
- Mayo Foundation for Medical Education and Research (MFMER)
- DKMS Group gGmbH
- The University of Chicago Medical Center
- Roswell Park Comprehensive Cancer Center
- University of Utah Health
- USC Norris Comprehensive Cancer Center
- Vanderbilt University Medical Center
- Moffitt Cancer Center
- Fred Hutchinson Cancer Center
TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF THE U.S. HEMATOLOGY ONCOLOGY MARKET 17
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 19
1.6 MARKETS COVERED 19
2 MARKET SEGMENTATION 22
2.1 MARKETS COVERED 22
2.2 U.S. HEMATOLOGY ONCOLOGY MARKET: GEOGRAPHICAL SCOPE 22
2.3 U.S. HEMATOLOGY ONCOLOGY MARKET: YEARS CONSIDERED FOR THE STUDY 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.6 U.S. HEMATOLOGY ONCOLOGY MARKET: MULTIVARIATE MODELLING 28
2.7 DBMR MARKET POSITION GRID 29
2.8 VENDOR SHARE ANALYSIS 30
2.9 SECONDARY SOURCES 31
2.10 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 34
4.1 PESTAL ANALYSIS 38
4.2 PORTERS FIVE FORCES ANALYSIS 39
4.3 INDUSTRY INSIGHTS 40
4.4 RWE/RWD PRACTICE, EREGISTERS, EHEALTH PROGRAMS FOR ONCO/AID/RARE DISEASES 45
4.4.1 PROMOTIONAL ACTIVITIES OF COMPANIES 45
4.5 TENDER SYSTEM AND CLINICAL GUIDELINES 47
4.5.1 ORGANIZATION OF THE TENDER SYSTEM 47
4.5.2 CLINICAL GUIDELINES (NATIONAL/REGIONAL/LOCAL HOSPITAL) 47
4.5.2.1 NATIONAL GUIDELINES (STANDARDIZED ACROSS THE U.S.) 48
4.5.2.2 REGIONAL GUIDELINES (STATE-LEVEL & RESEARCH INSTITUTION-BASED) 49
4.5.2.3 LOCAL HOSPITAL GUIDELINES (INSTITUTION-SPECIFIC PROTOCOLS) 49
4.6 MARKET CHARACTERISTICS (DECENTRALIZED/ HIGHLY FRAGMENTED) 51
?
5 NUMBER OF ONGOING CLINICAL TRIALS FOR EACH TREATMENT TYPE 52
5.1 TARGETED THERAPIES & SMALL MOLECULES 52
5.1.1 TYROSINE KINASE INHIBITORS (TKIS) 52
5.1.2 MONOCLONAL ANTIBODIES 53
5.2 IMMUNOTHERAPIES 753
5.2.1 CART CELL THERAPY 753
5.2.2 IMMUNE CHECKPOINT INHIBITORS 859
5.2.3 CYTOKINE THERAPY 956
5.3 CHEMOTHERAPY DRUGS 962
5.3.1 ALKYLATING AGENTS 962
5.3.2 ANTHRACYCLINES 1461
5.3.3 TOPOISOMERASE INHIBITORS 1462
5.3.4 VINCA ALKALOIDS 1977
5.4 STEM CELL TRANSPLANTATION 2366
5.4.1 AUTOLOGOUS STEM CELL TRANSPLANTATION 2366
5.4.2 ALLOGENEIC STEM CELL TRANSPLANTATION 2527
5.5 GENE THERAPY 2682
5.6 EXTRA DRUGS AS PER REQUIREMENT 2793
5.6.1 VENETECLAX HMA 2793
5.6.2 CAR NK CELLS 2803
5.6.3 MENIN INHIBITORS 2804
6 CUSTOMIZATION 2810
6.1 THERAPY CLASSIFICATION 2813
6.1.1 THERAPY PURPOSE 2813
6.1.1.1 THERAPIES DELAYING TRANSPLANT 2813
6.1.1.2 THERAPIES EXPANDING INDICATION FOR TRANSPLANT 2813
6.1.2 COST ANALYSIS 2814
6.2 MARKET INDUSTRY TRENDS AND FORECAST 2816
6.3 SHIFT IN CARE SETTINGS 2818
6.4 TREATMENT TYPES AS PER REQUIREMENT 2819
6.4.1 VENETOCLAX (HMA) COMBINATION 2819
6.4.2 CAR NK CELLS 2819
6.5 HEALTHCARE PROVIDERS AND FACILITIES 2822
6.5.1 PROVIDER MARKET: 2822
6.5.1.1 TOTAL ADDRESSABLE PROVIDER MARKET FOR HEMATOLOGIC MALIGNANCIES (AML, ALL, MDS, APLASTIC ANEMIA, SICKLE CELL DISEASE) 2822
6.5.1.2 NUMBER OF HEMATOLOGISTS/ONCOLOGISTS TREATING THESE CONDITIONS 2822
6.5.1.3 GEOGRAPHIC DISTRIBUTION OF THESE PROVIDERS 2822
6.5.1.4 PROVIDERS PRACTICING AT NON-TRANSPLANT CENTERS NEEDING TO REFER PATIENTS EXTERNALLY FOR TRANSPLANTS 2822
6.5.2 HEALTHCARE FACILITIES TRENDS: 2823
6.5.2.1 NUMBER OF HEALTHCARE FACILITIES EQUIPPED TO DELIVER EACH TREATMENT 2823
6.5.2.2 GEOGRAPHIC TRENDS IN THE NUMBER OF HEALTHCARE FACILITIES OVER DEFINED YEARS 2823
6.5.3 TRANSPLANT CENTERS 2824
7 U.S. HEMATOLOGY ONCOLOGY MARKET: REGULATIONS 2826
8 MARKET OVERVIEW 2827
8.1 DRIVERS 2829
8.1.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES TRANSFORMING HEMATOLOGY ONCOLOGY DETECTION AND TREATMENT APPROACHES 2829
8.1.2 DEVELOPMENT OF TARGETED THERAPIES AND IMMUNOTHERAPIES IN HEMATOLOGY ONCOLOGY CARE 2830
8.1.3 CONSOLIDATION OF HEMATOLOGY ONCOLOGY PRACTICES IMPROVING TREATMENT EFFICIENCY AND PATIENT OUTCOMES 2830
8.2 RESTRAINTS 2832
8.2.1 PATIENT NON-COMPLIANCE WITH TREATMENT REGIMENS IN HEMATOLOGY ONCOLOGY CARE 2832
8.2.2 LACK OF EARLY DETECTION IN HEMATOLOGY ONCOLOGY IMPEDING PROGRESS 2832
8.3 OPPORTUNITIES 2834
8.3.1 RISING INCIDENCE OF CANCER LEADS TO INCREASED DEMAND FOR TREATMENTS 2834
8.3.2 INCREASE IN THE NUMBER OF COLLABORATIVE PARTNERSHIPS THAT ACCELERATE ADVANCEMENTS IN CANCER TREATMENTS 2834
8.4 CHALLENGES 2836
8.4.1 RISING COSTS ASSOCIATED WITH THE CANCER TREATMENTS 2836
8.4.2 SHORTAGE OF THE HEALTHCARE PROFESSIONALS TRAINED IN HEMATOLOGY ONCOLOGY 2836
9 U.S. HEMATOLOGY ONCOLOGY MARKET, BY DISEASE TYPE 2838
9.1 OVERVIEW 2839
9.2 LYMPHOMA 2842
9.3 ACUTE MYELOID LEUKEMIA (AML) 2842
9.4 MYELODYSPLASTIC SYNDROMES (MDS) 2842
9.5 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 2843
9.6 SICKLE CELL DISEASE (SCD) 2843
9.7 OTHERS 2843
?
10 U.S. HEMATOLOGY ONCOLOGY MARKET, BY END USER 2844
10.1 OVERVIEW 2845
10.2 HOSPITALS 2848
10.3 SPECIALIZED CLINICS 2848
10.4 TRANSPLANT CENTERS 2848
10.5 PHARMACEUTICAL & BIOTECH COMPANIES 2848
10.6 OTHERS 2848
11 U.S. HEMATOLOGY ONCOLOGY MARKET, BY RACE 2849
11.1 OVERVIEW 2850
11.2 WHITE OR UNKNOWN RACE 2853
11.3 ETHNICALLY DIVERSE 2854
11.3.1 BLACK OR AFRICAN AMERICAN 2854
11.3.2 HISPANIC 2854
11.3.3 ASIAN OR PACIFIC ISLANDER (INCLUDING HAWAIIAN) 2854
11.3.4 AMERICAN INDIAN OR ALASKA NATIVE 2854
11.3.5 MULTIPLE RACE 2854
12 U.S. HEMATOLOGY ONCOLOGY MARKET, BY TREATMENT TYPE 2855
12.1 OVERVIEW 2856
12.2 TARGETED THERAPIES & SMALL MOLECULES 2860
12.2.1 TYROSINE KINASE INHIBITORS (TKIS) 2861
12.2.1.1 IMATINIB 2861
12.2.1.2 DASATINIB 2861
12.2.1.3 NILOTINIB 2861
12.2.1.4 IBRUTINIB 2861
12.2.1.5 ACALABRUTINIB 2861
12.2.2 MONOCLONAL ANTIBODIES 2862
12.2.2.1 RITUXIMAB 2862
12.2.2.2 OBINUTUZUMAB 2862
12.2.2.3 OFATUMUMAB 2862
12.2.2.4 DARATUMUMAB 2862
12.2.2.5 ELOTUZUMAB 2862
12.2.3 PROTEASOME INHIBITORS 2863
12.2.3.1 BORTEZOMIB 2863
12.2.3.2 CARFILZOMIB 2863
12.2.3.3 IXAZOMIB 2863
12.2.4 FLT3 INHIBITORS 2864
12.2.4.1 MIDOSTAURIN 2864
12.2.4.2 GILTERITINIB 2864
12.3 IMMUNOTHERAPIES 2865
12.3.1 CART CELL THERAPY 2866
12.3.1.1 TISAGENLECLEUCEL 2866
12.3.1.2 AXICABTAGENE CILOLEUCEL 2866
12.3.1.3 BREXUCABTAGENE AUTOLEUCEL 2866
12.3.1.4 LISOCABTAGENE MARALEUCEL 2866
12.3.2 IMMUNE CHECKPOINT INHIBITORS 2867
12.3.2.1 PEMBROLIZUMAB 2867
12.3.2.2 NIVOLUMAB 2867
12.3.3 BISPECIFIC ANTIBODIES 2868
12.3.4 CYTOKINE THERAPY 2869
12.3.4.1 INTERFERONS 2869
12.3.4.2 INTERLEUKINS 2869
12.3.4.3 OTHERS 2869
12.4 CHEMOTHERAPY DRUGS 2870
12.4.1 ALKYLATING AGENTS 2871
12.4.1.1 CYCLOPHOSPHAMIDE 2871
12.4.1.2 CHLORAMBUCIL 2871
12.4.1.3 BENDAMUSTINE 2871
12.4.2 ANTIMETABOLITES 2872
12.4.2.1 CYTARABINE (ARA C) 2872
12.4.2.2 METHOTREXATE 2872
12.4.2.3 FLUDARABINE 2872
12.4.2.4 MERCAPTOPURINE 2872
12.4.3 ANTHRACYCLINES 2873
12.4.3.1 DOXORUBICIN 2873
12.4.3.2 DAUNORUBICIN 2873
12.4.3.3 IDARUBICIN 2873
12.4.4 TOPOISOMERASE INHIBITORS 2874
12.4.4.1 ETOPOSIDE 2874
12.4.4.2 TOPOTECAN 2874
12.4.5 VINCA ALKALOIDS 2875
12.4.5.1 VINCRISTINE 2875
12.4.5.2 VINBLASTINE 2875
12.5 STEM CELL TRANSPLANTATION 2876
12.5.1 AUTOLOGOUS STEM CELL TRANSPLANTATION 2876
12.5.2 ALLOGENEIC STEM CELL TRANSPLANTATION 2877
12.5.2.1 MATCHED RELATED DONOR (MRD) 2877
12.5.2.2 MATCHED UNRELATED DONOR (MUD) 2877
12.5.2.3 HAPLOIDENTICAL DONOR 2877
12.5.2.4 OTHERS 2877
12.6 GENE THERAPY 2878
12.6.1 CRISPR-CAS9 BASED THERAPIES 2878
12.6.2 LENTIGLOBIN BB305 2878
12.6.3 OTHERS 2878
13 U.S. HEMATOLOGY ONCOLOGY MARKET: COMPANY LANDSCAPE 2879
13.1 COMPANY SHARE ANALYSIS: U.S. 2879
14 SWOT ANALYSIS 2880
15 COMPANY PROFILES 2881
15.1 GILEAD SCIENCE, INC. 2881
15.1.1 COMPANY SNAPSHOT 2881
15.1.2 REVENUE ANALYSIS 2882
15.1.3 PRODUCT PORTFOLIO 2882
15.1.4 RECENT DEVELOPMENT 2883
15.2 ABBVIE INC. 2884
15.2.1 COMPANY SNAPSHOT 2884
15.2.2 REVENUE ANALYSIS 2884
15.2.3 PRODUCT PORTFOLIO 2885
15.2.4 RECENT DEVELOPMENT 2886
15.3 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 2887
15.3.1 COMPANY SNAPSHOT 2887
15.3.2 REVENUE ANALYSIS 2887
15.3.3 PIPELINE PRODUCT PORTFOLIO 2888
15.3.4 RECENT/NEWS 2889
15.4 ASTRAZENECA 2891
15.4.1 COMPANY SNAPSHOT 2891
15.4.2 REVENUE ANALYSIS 2892
15.4.3 PRODUCT PORTFOLIO 2892
15.4.4 RECENT DEVELOPMENT 2893
15.5 SANOFI 2894
15.5.1 COMPANY SNAPSHOT 2894
15.5.2 REVENUE ANALYSIS 2895
15.5.3 PRODUCT PORTFOLIO 2895
15.5.4 RECENT DEVELOPMENT 2896
15.6 ASTELLAS PHARMA INC. 2898
15.6.1 COMPANY SNAPSHOT 2898
15.6.2 REVENUE ANALYSIS 2899
15.6.3 PRODUCT PORTFOLIO 2899
15.6.4 RECENT DEVELOPMENT 2900
15.7 BAYER AG 2902
15.7.1 COMPANY SNAPSHOT 2902
15.7.2 REVENUE ANALYSIS 2902
15.7.3 PRODUCT PORTFOLIO 2903
15.7.4 RECENT DEVELOPMENT 2903
15.8 BLUEBIRD BIO, INC. 2904
15.8.1 COMPANY SNAPSHOT 2904
15.8.2 REVENUE ANALYSIS 2905
15.8.3 PRODUCT PORTFOLIO 2905
15.8.4 RECENT DEVELOPMENT 2905
15.9 BRISTOL-MYERS SQUIBB COMPANY 2907
15.9.1 COMPANY SNAPSHOT 2907
15.9.2 REVENUE ANALYSIS 2908
15.9.3 PRODUCT PORTFOLIO 2908
15.9.4 RECENT NEWS 2909
15.10 CITY OF HOPE. 2911
15.10.1 COMPANY SNAPSHOT 2911
15.10.2 SERVICE PORTFOLIO 2911
15.10.3 RECENT DEVELOPMENT 2912
15.11 CLEVELAND CLINIC TAUSSIG CANCER 2913
15.11.1 COMPANY SNAPSHOT 2913
15.11.2 SERVICES PORTFOLIO 2913
15.11.3 RECENT DEVELOPMENT 2915
15.12 CRISPR THERAPEUTICS 2916
15.12.1 COMPANY SNAPSHOT 2916
15.12.2 REVENUE ANALYSIS 2916
15.12.3 PRODUCT PORTFOLIO 2917
15.12.4 RECENT DEVELOPMENT 2917
15.13 DANA-FARBER CANCER INSTITUTE, INC. 2918
15.13.1 COMPANY SNAPSHOT 2918
15.13.2 SERVICE PORTFOLIO 2918
15.13.3 RECENT DEVELOPMENT 2918
15.14 DKMS GROUP GGMBH 2920
15.14.1 COMPANY SNAPSHOT 2920
15.14.2 PRODUCT PORTFOLIO 2920
15.14.3 RECENT DEVELOPMENT 2920
?
15.15 EDITAS MEDICINE 2922
15.15.1 COMPANY SNAPSHOT 2922
15.15.2 REVENUE ANALYSIS 2922
15.15.3 PRODUCT PORTFOLIO 2923
15.15.4 RECENT NEWS 2923
15.16 ELI LILLY AND COMPANY 2924
15.16.1 COMPANY SNAPSHOT 2924
15.16.2 REVENUE ANALYSIS 2925
15.16.3 PRODUCT PORTFOLIO 2925
15.16.4 RECENT DEVELOPMENT 2926
15.17 F. HOFFMANN-LA ROCHE LTD. 2927
15.17.1 COMPANY SNAPSHOT 2927
15.17.2 REVENUE ANALYSIS 2927
15.17.3 PRODUCT PORTFOLIO 2928
15.17.4 RECENT DEVELOPMENT 2930
15.18 FRED HUTCHINSON CANCER CENTER 2931
15.18.1 COMPANY SNAPSHOT 2931
15.18.2 SERVICE PORTFOLIO 2931
15.18.3 RECENT DEVELOPMENT 2932
15.19 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MFMER) 2933
15.19.1 COMPANY SNAPSHOT 2933
15.19.2 PRODUCT PORTFOLIO 2933
15.19.3 RECENT DEVELOPMENT/NEWS 2933
15.20 MEMORIAL SLOAN KETTERING CANCER CENTER 2935
15.20.1 COMPANY SNAPSHOT 2935
15.20.2 SERVICE PORTFOLIO 2935
15.20.3 RECENT UPDATES 2937
15.21 MERCK & CO., INC. 2938
15.21.1 COMPANY SNAPSHOT 2938
15.21.2 REVENUE ANALYSIS 2938
15.21.3 PRODUCT PORTFOLIO 2939
15.21.4 RECENT DEVELOPMENT 2939
15.22 MOFFITT CANCER CENTER 2940
15.22.1 COMPANY SNAPSHOT 2940
15.22.2 PRODUCT PORTFOLIO 2940
15.22.3 RECENT DEVELOPMENT/NEWS 2941
?
15.23 NOVARTIS AG 2942
15.23.1 COMPANY SNAPSHOT 2942
15.23.2 REVENUE ANALYSIS 2942
15.23.3 PRODUCT PORTFOLIO 2943
15.23.4 RECENT DEVELOPMENT 2944
15.24 PFIZER INC. 2945
15.24.1 COMPANY SNAPSHOT 2945
15.24.2 REVENUE ANALYSIS 2945
15.24.3 PRODUCT PORTFOLIO 2946
15.24.4 RECENT DEVELOPMENT 2947
15.25 REGENERON PHARMACEUTICALS INC. 2948
15.25.1 COMPANY SNAPSHOT 2948
15.25.2 REVENUE ANALYSIS 2948
15.25.3 PRODUCT PORTFOLIO 2949
15.25.4 RECENT DEVELOPMENT 2950
15.26 ROSEWELL PARK COMPREHENSIVE CANCER CENTER 2951
15.26.1 COMPANY SNAPSHOT 2951
15.26.2 SERVICE PORTFOLIO 2951
15.26.3 RECENT DEVELOPMENT 2954
15.27 STANFORD MEDICINE 2955
15.27.1 COMPANY SNAPSHOT 2955
15.27.2 SERVICE PORTFOLIO 2955
15.27.3 RECENT UPDATES 2956
15.28 THE JOHNS HOPKINS UNIVERSITY, THE JOHNS HOPKINS HOSPITAL, AND JOHNS HOPKINS HEALTH SYSTEM 2957
15.28.1 COMPANY SNAPSHOT 2957
15.28.2 PRODUCT PORTFOLIO 2957
15.28.3 RECENT DEVELOPMENTS 2958
15.29 THE UNIVERSITY OF CHICAGO MEDICAL CENTER 2959
15.29.1 COMPANY SNAPSHOT 2959
15.29.2 SERVICE PORTFOLIO 2959
15.29.3 RECENT DEVELOPMENT 2960
15.30 THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 2961
15.30.1 COMPANY SNAPSHOT 2961
15.30.2 SERVICE PORTFOLIO 2961
15.30.3 RECENT UPDATES/NEWS 2965
15.31 THE CHILDREN'S HOSPITAL OF PHILADELPHIA 2966
15.31.1 COMPANY SNAPSHOT 2966
15.31.2 SERVICE PORTFOLIO 2966
15.31.3 RECENT DEVELOPMENT 2968
15.32 UCLA HEALTH 2969
15.32.1 COMPANY SNAPSHOT 2969
15.32.2 PRODUCT PORTFOLIO 2969
15.32.3 RECENT DEVELOPMENT/NEWS 2970
15.33 UNIVERSITY OF UTAH HEALTH 2971
15.33.1 COMPANY SNAPSHOT 2971
15.33.2 SERVICE PORTFOLIO 2971
15.33.3 RECENT DEVELOPMENT 2971
15.34 USC NORRIS COMPREHENSIVE CANCER 2972
15.34.1 COMPANY SNAPSHOT 2972
15.34.2 PRODUCT PORTFOLIO 2972
15.34.3 RECENT DEVELOPMENT/NEWS 2973
15.35 VANDERBILT-INGRAM CANCER CENTER 2974
15.35.1 COMPANY SNAPSHOT 2974
15.35.2 PRODUCT PORTFOLIO 2974
15.35.3 RECENT DEVELOPMENT 2974
15.36 VERTEX PHARMACEUTICALS INCORPORATED 2976
15.36.1 COMPANY SNAPSHOT 2976
15.36.2 REVENUE ANALYSIS 2977
15.36.3 PRODUCT PORTFOLIO 2977
15.36.4 RECENT DEVELOPMENT 2977
16 QUESTIONNAIRE 2979
17 RELATED REPORTS 2982
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security